ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1151

Revised IWOS Criteria for Ocular Sarcoidosis: A 2019 Review of the 2009 Criteria in a Study of 384 Patients from a Single University Hospital

Carmen Lasa1, Jorge Javier Gaitán2, Lara Sanchez-Bilbao3, David Martínez-Lopez4, Inigo Gonzalez-Mazon3, Jose Luis Martin-Varillas5, Rosalía Demetrio2, Raul Fernandez-Ramon2 and Ricardo Blanco6, 1Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Hospital Universitario Marques de Valdecilla, Santander, Spain, 4Hospital Sierrallana, Torrelavega, Spain, 5Hospital de Laredo, Laredo, Spain, 6Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

Meeting: ACR Convergence 2023

Keywords: Diagnostic criteria

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1124–1154) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Sarcoidosis is a systemic inflammatory disorder which involves many organs, including eyes. Uveitis and optic neuropathy are the main manifestations. International Workshop on Ocular Sarcoidosis (IWOS) criteria for diagnosis of ocular sarcoidosis (OS) were first published in 2009 and revised in 2019. (question-based survey and panel discussion). IWOS criteria is a remarkable tool to relate uveitis to sarcoidosis, especially when ocular is the first manifestation in the systemic disease. Due to the consequences of OS, identify and initiate appropriate therapy is essential.

Methods: We studied a large cohort (n=384) of all consecutive patients diagnosed with sarcoidosis from January 1, 1999, to December 31, 2019. Finally, 344 patients were included according to the ATS/ERS/WASOG criteria. First (2009) and revised (2019) IWOS criteria were applied to patients diagnosed with Sarcoidosis and ocular symptoms and the results were compared in both groups for our population. Concordance between 2009 and 2019 IWOS criteria was evaluated by calculating Cohen´s kappa coefficient.

Results: 65 (51% men) of 344 patients had ocular involvement (18.9%), mean age 56.7±16.3 years. As for nationality, 92.3% were Spaniard and 7.7% were South American. A positive biopsy for sarcoidosis was obtained in 75.4% (n=49) and a negative biopsy in 6.2% (n=4). There was no statistically significative difference between diagnostic groups for IWOS 2009/IWOS 2019 in age (p=0.738/p=0.495), sex (p=0.534/p=0.459) nor nationality (p=0.529/p=0.393). When applied 2009 IWOS criteria, 60% (39 patients) met any of the diagnostic categories (43.1% Definitive, 13.8% Presumed, 1.5% Probable, 1.5% Possible). When 2019 IWOS criteria was applied, 53.8% (35 patients) met any of the new diagnostic categories (43.1% Definitive, 7.7% Presumed, 3.1% Probable). Sensitivity for IWOS 2009 was 0.6 and for IWOS 2019 was 0.53. There was statistically significative concordance between 2009 and 2019 IWOS criteria (p< 0.0001) with a strong consistency level (kappa = 0.824). When analyzing IWOS categories separately, we found total concordance in the Definitive category. Probable and Possible categories in 2009 criteria have been merged in only probable in 2019 criteria and there is a total concordance when comparing both. Presumed category represent the bigger change in the revised criteria. We found statistically significative concordance (p=0.000008) with a moderate consistency level (kappa = 0,524).

Conclusion: The revised 2019 IWOS criteria is less sensitive in our population; however, the main difference is in the category Presumed: the requirement of at least 2 intraocular signs of uveitis led to a change of 9 patients (13,8%) in 2009 IWOS down to 5 (7.7%) in 2019. In our population IWOS criteria is still has a low sensitivity.

Supporting image 2


Disclosures: C. Lasa: None; J. Gaitán: None; L. Sanchez-Bilbao: None; D. Martínez-Lopez: None; I. Gonzalez-Mazon: None; J. Martin-Varillas: None; R. Demetrio: None; R. Fernandez-Ramon: None; R. Blanco: AbbVie, 5, 6, Amgen, 6, AstraZeneca, 2, BMS, 6, Eli Lilly, 6, Galapagos, 2, 6, Janssen, 2, 6, MSD, 6, Novartis, 2, 6, Pfizer, 2, 6, Roche, 5, 6, Sanofi, 6.

To cite this abstract in AMA style:

Lasa C, Gaitán J, Sanchez-Bilbao L, Martínez-Lopez D, Gonzalez-Mazon I, Martin-Varillas J, Demetrio R, Fernandez-Ramon R, Blanco R. Revised IWOS Criteria for Ocular Sarcoidosis: A 2019 Review of the 2009 Criteria in a Study of 384 Patients from a Single University Hospital [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/revised-iwos-criteria-for-ocular-sarcoidosis-a-2019-review-of-the-2009-criteria-in-a-study-of-384-patients-from-a-single-university-hospital/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/revised-iwos-criteria-for-ocular-sarcoidosis-a-2019-review-of-the-2009-criteria-in-a-study-of-384-patients-from-a-single-university-hospital/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology